CAR-T cell therapy — a treatment that reprograms a patient's own immune cells to recognize and attack cancer — has already transformed outcomes for several blood cancers. Now, partner oncology centers in Tianjin and across China are enrolling patients in new clinical trials that extend the technology to solid tumors, including lung, liver, gastric and pancreatic cancers.
Early-phase results presented at recent conferences show meaningful tumor shrinkage in a subset of patients, along with manageable side-effect profiles under experienced supportive-care teams. Researchers are combining CAR-T with checkpoint inhibitors and local therapies to overcome the hostile environment that solid tumors build around themselves.
For international patients, participation in these trials can offer access to treatment that is unavailable or unavailable at any price in their home country. MyMedTour coordinates directly with trial investigators: we review eligibility criteria, translate medical records, arrange the pre-screening workup and support patients throughout the multi-week treatment and monitoring period.
Patients interested in CAR-T trials should prepare recent pathology reports, imaging discs and a summary of prior treatments — our physicians use these to match the case with the most suitable open protocol.